The Riddle of the Sphinx: Progress in Leptomeningeal Metastasis of Non–Small Cell Lung Cancer

Leptomeningeal metastasis (LM) is a serious complication of advanced non–small cell lung cancer (NSCLC), and the incidence of LM has been increasing yearly in recent times. There is no consensus on the best treatment modality for LM, which underscores a difficult problem in the management of advanced NSCLC patients. The existing treatments include molecular targeted therapy, systemic chemotherapy, local radiotherapy, antivascular tumor therapy, intrathecal chemotherapy, and immunotherapy, but their efficacy is not satisfactory. In this article, we briefly describe the clinical manifestations, diagnosis, and treatment of NSCLC-LM and discuss progress regarding evaluation of the efficacy of LM treatment to better provide a necessary reference for clinical practice and clinical trial evaluation.

[1]  Paola Anna Jablonska,et al.  Management of brain metastases in non-small cell lung cancer without actionable driver mutations—the need to dive deeper in the right ‘pool’ , 2023, Translational lung cancer research.

[2]  Liwu Fu,et al.  Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance , 2022, Journal of hematology & oncology.

[3]  M. Fang,et al.  Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer , 2022, Clinical Neurology and Neurosurgery.

[4]  Jiajia Wu,et al.  Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance , 2022, International journal of molecular sciences.

[5]  Sung Soo Ahn,et al.  Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging. , 2022, Journal of neurosurgery.

[6]  Xue Yang,et al.  Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment. , 2022, Lung cancer.

[7]  M. Guan,et al.  CEACAM6 serves as a biomarker for leptomeningeal metastasis in lung adenocarcinoma , 2022, Cancer medicine.

[8]  Man Li,et al.  Sequencing of cerebrospinal fluid in non‐small‐cell lung cancer patients with leptomeningeal metastasis: A systematic review , 2022, Cancer medicine.

[9]  Fancui Meng,et al.  Molecular dynamics simulations of a central nervous system-penetrant drug AZD3759 with lipid bilayer , 2022, Journal of Molecular Modeling.

[10]  J. Vredenburgh,et al.  Leptomeningeal Metastasis from Non-Small Cell Lung Cancer and Current Landscape of Treatments. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  T. Szekeres,et al.  Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial , 2022, Nature Medicine.

[12]  X. Qin,et al.  The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer , 2022, Journal of Cancer Research and Clinical Oncology.

[13]  N. Husain,et al.  Liquid biopsy in CNS tumors: Current status & future perspectives , 2022, Indian journal of pathology & microbiology.

[14]  P. Wen,et al.  Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort. , 2022, Neuro-oncology.

[15]  F. Hirsch,et al.  Consensus for HER2 alterations testing in non-small-cell lung cancer , 2022, ESMO open.

[16]  R. Stupp,et al.  Leptomeningeal metastases: the future is now , 2022, Journal of Neuro-Oncology.

[17]  M. Cong,et al.  Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis , 2022, Frontiers in Oncology.

[18]  A. Tan,et al.  Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. E. Pedreira,et al.  Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid , 2022, Cancers.

[20]  Kecheng Zhang,et al.  AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1 , 2021, Bioengineered.

[21]  Ping Wang,et al.  Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  H. Cai,et al.  Unique genomic alterations of cerebrospinal fluid cell-free DNA are critical for targeted therapy of non-small cell lung cancer with leptomeningeal metastasis. , 2021, Genomics.

[23]  A. Giobbie-Hurder,et al.  Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis , 2021, Nature Communications.

[24]  Yi-long Wu,et al.  Intrathecal Pemetrexed: Another Potential Treatment Modality for Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases? , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  I. Azar,et al.  Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer , 2021, Lung Cancer.

[26]  P. Jänne,et al.  Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. , 2021, The New England journal of medicine.

[27]  Xiaoqin Huang,et al.  Sensorineural Hearing Loss as the Prominent Symptom in Meningeal Carcinomatosis , 2021, Current oncology.

[28]  Jiewen Zhang,et al.  Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with EGFR-Mutated Non-Small-Cell Lung Cancer Regardless of Cerebrospinal Fluid T790M Mutational Status , 2021, Evidence-based complementary and alternative medicine : eCAM.

[29]  J. Qin,et al.  HER2 exon 20 insertion mutations in lung adenocarcinoma with leptomeningeal metastasis: a case report and response to poziotinib. , 2021, Annals of palliative medicine.

[30]  F. Gao,et al.  Efficacy and Safety of Intrathecal Pemetrexed Combined with Dexamethasone for Treating TKI-failed Leptomeningeal Metastases from EGFR-mutant NSCLC-A Prospective Open-label Single-arm Phase I/II Clinical Trial (unique identifier: ChiCTR1800016615). , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  G. Zadeh,et al.  Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors , 2021, International journal of molecular sciences.

[32]  Yi-long Wu,et al.  Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. , 2021, European journal of cancer.

[33]  S. Ou,et al.  Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  K. Pantel,et al.  Liquid Biopsy: From Discovery to Clinical Application. , 2021, Cancer discovery.

[35]  Thomas M. Durcan,et al.  Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation , 2021, Neurotherapeutics.

[36]  S. Chandarlapaty,et al.  Unlocking the potential of antibody–drug conjugates for cancer therapy , 2021, Nature Reviews Clinical Oncology.

[37]  Ying Cheng,et al.  Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study , 2021, Targeted Oncology.

[38]  P. Siegel,et al.  The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers , 2021, Cancers.

[39]  Q. Miao,et al.  Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis. , 2020, Annals of palliative medicine.

[40]  Junhong Zhang,et al.  Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis , 2020, Journal of Cancer.

[41]  Longhua Chen,et al.  Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study , 2020, Radiation oncology.

[42]  Haiying Cheng,et al.  Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations , 2020, Current Treatment Options in Oncology.

[43]  K. Pantel,et al.  Liquid biopsies: Potential and challenges , 2020, International journal of cancer.

[44]  J. Ahn,et al.  Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[45]  Hua He,et al.  Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study , 2020, Therapeutic advances in medical oncology.

[46]  P. Solár,et al.  Choroid plexus and the blood–cerebrospinal fluid barrier in disease , 2020, Fluids and Barriers of the CNS.

[47]  P. Jänne,et al.  Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. , 2020, Cancer discovery.

[48]  A. Shaw,et al.  Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer , 2020, Targeted Oncology.

[49]  Ying Cheng,et al.  Osimertinib for patients with leptomeningeal metastases associated with epidermal growth factor receptor T790M positive advanced NSCLC: the AURA LM analysis. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  N. Schork,et al.  Circulating tumor DNA as an early cancer detection tool. , 2019, Pharmacology & therapeutics.

[51]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[52]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[53]  L. Vanzin,et al.  Treatments , 2019, Understanding Conduct Disorder and Oppositional-Defiant Disorder.

[54]  Wei Li,et al.  A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer , 2019, Front. Oncol..

[55]  Yi-long Wu,et al.  A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. , 2019, Lung cancer.

[56]  Yi-long Wu,et al.  Clinical Utility of Cerebrospinal Fluid Cell‐Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK‐Rearranged NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  M. J. van den Bent,et al.  How we treat patients with leptomeningeal metastases , 2019, ESMO Open.

[58]  F. Cotton,et al.  Pathogenesis of peri-tumoral edema in intracranial meningiomas , 2019, Neurosurgical Review.

[59]  P. Wen,et al.  The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. , 2019, Neuro-oncology.

[60]  D. Morgensztern,et al.  Lorlatinib: a new-generation drug for ALK-positive NSCLC. , 2018, The Lancet. Oncology.

[61]  P. Aung,et al.  Circulating tumour DNA, microRNA and metabolites in cerebrospinal fluid as biomarkers for central nervous system malignancies , 2018, Journal of Clinical Pathology.

[62]  Meizhuo Zhang,et al.  Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. , 2018, Lung cancer.

[63]  M. Ahluwalia,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. , 2018, The oncologist.

[64]  A. Shaw,et al.  Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  Fareed Jumah,et al.  Blood brain barrier: A review of its anatomy and physiology in health and disease , 2018, Clinical anatomy.

[66]  S. Novello,et al.  Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer , 2018, Front. Oncol..

[67]  J. Vansteenkiste,et al.  Genetic profiling of cell-free DNA from cerebrospinal fluid: opening the barrier to leptomeningeal metastasis in EGFR-mutant NSCLC. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[69]  D. Planchard AZD3759 for CNS metastases in EGFR-mutant lung cancer. , 2017, The Lancet. Respiratory medicine.

[70]  J. Ahn,et al.  Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. , 2017, The Lancet. Respiratory medicine.

[71]  Steven H. Liang,et al.  Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET , 2017, Molecular imaging.

[72]  G. Zalcman,et al.  Bevacizumab in advanced lung cancer: state of the art. , 2017, Future oncology.

[73]  R. Henriksson,et al.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  Steven H. Liang,et al.  Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib , 2017, Nature Communications.

[75]  S. Xiong,et al.  Determination of AZD3759 in rat plasma and brain tissue by LC–MS/MS and its application in pharmacokinetic and brain distribution studies , 2017, Journal of pharmaceutical and biomedical analysis.

[76]  M. Berger,et al.  Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  L. Deangelis,et al.  Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors , 2017, Neuro-oncology.

[78]  B. Besse,et al.  Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. , 2017, Cancer treatment reviews.

[79]  M. Ahn,et al.  AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases , 2016, Science Translational Medicine.

[80]  Yi-long Wu,et al.  Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[81]  F. Cappuzzo,et al.  Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  K. Ichikado,et al.  Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer. , 2016, Lung cancer.

[83]  de Goeij,et al.  Antibody-drug conjugates in cancer , 2016 .

[84]  Jae-Won Hyun,et al.  Leptomeningeal metastasis: Clinical experience of 519 cases. , 2016, European journal of cancer.

[85]  H. Groen,et al.  Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis. , 2015, Lung cancer.

[86]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Hiroshi Sakamoto,et al.  Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases , 2014, Cancer Chemotherapy and Pharmacology.

[88]  Damoun Nassehi Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. , 2013, Danish medical journal.

[89]  Su Jin Lee,et al.  Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[90]  J. Bonneterre,et al.  Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis , 2012, BMC Clinical Pathology.

[91]  A. Demopoulos,et al.  Leptomeningeal Metastases , 2012, Current Treatment Options in Oncology.

[92]  J. Ahn,et al.  Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats , 2011, Cancer Chemotherapy and Pharmacology.

[93]  S. Kobayashi,et al.  CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[95]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  OUP accepted manuscript , 2022, Neuro-Oncology.

[97]  Leptomeningeal , 2021, Encyclopedia of Gerontology and Population Aging.

[98]  Ying Cheng,et al.  Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[99]  P. Brastianos,et al.  Leptomeningeal metastasis from systemic cancer: Review and update on management , 2018, Cancer.

[100]  Tamara Wurst Liquid Biopsies. , 2018, Genetic testing and molecular biomarkers.

[101]  M. Chamberlain,et al.  Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. , 2017, Neuro-oncology.

[102]  A. Kleijn,et al.  Cerebrospinal fluid biomarkers of malignancies located in the central nervous system. , 2017, Handbook of clinical neurology.

[103]  Kazuhisa Takahashi,et al.  Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. , 2016, Respiratory investigation.

[104]  Hadano Naoto 膵癌術後患者におけるcirculating tumor DNA検出の意義 , 2016 .

[105]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.